@pittcp3.bsky.social
Center for Pharmaceutical Policy and Prescribing at the University of Pittsburgh. Our research helps improve quality, safety, & efficiency of medication use.
New preprint co-authored by CP3’s @jennylociganic.bsky.social: PGx can help match patients to safer opioids. An ensemble ML model (XGB+SVM-RBF) best predicted PGx uptake (AUC 79.6%). With further validation, it could support real-world clinical decision tools. www.medrxiv.org/content/10.1...
02.10.2025 18:23 — 👍 0 🔁 0 💬 0 📌 0
New study co-authored by CP3’s Dr. Ted Park finds over 1 in 5 opioid/benzo-naïve patients started 🆕Rx after surgery, while half with prior use continued. Many fills reflect preexisting use—highlighting need for tailored risk management.
More @acsjacs.bsky.social:
journals.lww.com/journalacs/a...
🆕study in 🫀co-authored by CP3’s @timandersonmd.bsky.social examines acute ⬆️ #bloodpressure in hospital settings. Clinicians often don’t treat it, citing uncertainty about dx thresholds & risks—highlighting need for clearer guidelines & decision support tools.
More: heart.bmj.com/content/earl...
New study co-authored by CP3’s Dr. Coleman Drake finds that a 2008 federal #methadone supply restriction led patients to switch to safer formulations, preventing an estimated 1,600 #overdose deaths over two years.
Read more: www.sciencedirect.com/science/arti...
We’re excited to share the launch of CP3’s new website, now hosted on the @openscholar.bsky.social platform! The site offers a fresh, unified look with other Pitt Centers and Institutes and is designed to spotlight CP3’s research projects.
Take a look!
cp3.pitt.edu
🆕preprint co-authored by CP3’s Dr. Julie Donohue finds ACA #Medicaid expansion in NJ & PA led to large immediate increases in Medicaid enrollment among people using homelessness assistance services, especially those with frequent service contact.
www.researchsquare.com/article/rs-6...
🆕study w/ CP3 co-authors shows prescribers responded to the 2018-19 ARB (valsartan, losartan, irbesartan) recalls with large reductions in valsartan fills (↓ 57-59%), offset by increases in other ARBs. No major shift toward non-ARB antihypertensives.
journals.lww.com/lww-medicalc...
🆕analysis led by CP3's Dr. Katie Suda & Tate Miner & team shows National Action Plan implementation wasn't associated with changes in antibiotic sales after 2 years.
@mina-t.bsky.social @pittgim.bsky.social
Read more @ichejournal.bsky.social:
www.cambridge.org/core/journal...
New @journalgim.bsky.social study: VA clinicians cite evidence uncertainty, patient expectations, and system barriers as drivers of low-value care. Clearer guidance, education & aligned incentives may help reduce it.
link.springer.com/article/10.1...
🆕paper, co-authored by CP3's @timandersonmd.bsky.social, describes findings that inpatient orthostatic hypotension was most often recognized after admission, but etiology and management differed across service lines.
Read more: onlinelibrary.wiley.com/doi/10.1111/...
New analysis suggests restrictive state #opioid treatment program regulations limit geographic access to #methadone maintenance treatment & easing these restrictions could expand access.
Read more in Health Affairs:
www.healthaffairs.org/doi/10.1377/...
Though there were no differences in ED use or all-cause mortality, #Medicaid prescription cap policies were associated with increased hospitalization risk.
Read more: www.sciencedirect.com/science/arti...
More than 1 in 10 opioid-naive #veterans having curative cancer surgery developed new persistent #opioid use, per a new study co-authored by CP3's Dr. Katie Suda. Optimizing pain management is key to reducing long-term opioid risks.
More: acsjournals.onlinelibrary.wiley.com/doi/10.1002/...
Results suggest private equity acquisitions don't change #methadone access. Authors, incl CP3's Dr. Bryant Shuey, recommend policy makers be wary of those that "might benefit from the status quo on policies that seek to expand methadone access."
More: www.healthaffairs.org/doi/10.1377/...
Not much is known about patterns of opioid prescribing & vaso-occlusive crises among individuals with sickle cell disease. CP3's Drs. Ted Park & Terri Newman & team sought to change that with this analysis.
Learn what they found: www.thelancet.com/journals/lan...
CP3’s Dr. Tom Radomski received a new VA Merit grant to lead EVOLV-Rx VA, a study aimed at reducing low-value prescribing in VA Community Living Centers. The project will use an EVOLV-Rx dashboard to support pharmacists in making deprescribing recommendations. #Veterans #Deprescribing
05.09.2025 14:52 — 👍 1 🔁 1 💬 0 📌 0
🆕analysis from CP3's Dr. Ravy Vajravelu, @timandersonmd.bsky.social, Bridget Mayrer, & team examined the implications of recdent iron deficiency guidelines for the prevalence & management of iron deficiency anemia.
Read more @jamainternalmed.com:
jamanetwork.com/journals/jam...
Stimulant prescribing is ⬆️, leading to concerns about overprescribing/misuse. CP3's @timandersonmd.bsky.social & team examined post-Covid stimulant prescribing trends & noted ⬆️prescriptions by nurse practitioners & ⬆️marketing to clinicians.
More @jamapediatrics.com: jamanetwork.com/journals/jam...
New paper co-authored by CP3’s #MachineLearning expert @jennylociganic.bsky.social presents a model that effectively predicts and stratifies risk of hepatitis C infection using ML algorithms—offering a powerful tool for targeted screening.
Read more: academic.oup.com/ofid/article...
Congrats to @walidgellad.bsky.social & the mPROVEN study team on a new award to create a playbook for ethical use of #machinelearning based #opioid #riskprediction models, building on years of expertise developing & deploying these tools in a variety of care settings.
www.cp3.pitt.edu/mproven
New study co-authored by CP3’s @timandersonmd.bsky.social finds orthostatic hypotension in hospitalized patients is often under-recognized, with only 1/3 resolving by discharge. Highlights need for better detection & treatment.
Read more: onlinelibrary.wiley.com/doi/10.1111/...
Congrats to Dr. Kawtar Zouaidi (UT Health Houston) of Dr. Katie Suda's research team! Dr. Zouaidi's poster, “Adverse outcomes associated with high-risk medication administered to children during the dental visit, 2014-2020," received the Drug Utilization/HSR poster award at #ISPE!
27.08.2025 19:22 — 👍 0 🔁 0 💬 0 📌 0
Posters presented by study team members Kawtar Zouaidi (L, UT Health Houston) & Yilei Liu (R) were chosen as spotlight posters. Congrats!
#ISPE #pharmacoepi
2/2
CP3 Associate Director Dr. Katie Suda's team presented work from her NIH-funded Pediatric Adverse Event Risk Reduction R01 at the annual meeting of the International Society for Pharmacoepidemiology.
#ISPE #pharmacoepi
1/2
🆕analysis found relationships between #antidepressant dose & fall risk, underscoring the importance of starting antidepressants at the lowest effective dose & monitoring fall risk.
More: bmcmedicine.biomedcentral.com/articles/10....
Co-authored by CP3's Dr. Ted Park & @jennylociganic.bsky.social
CP3's @timandersonmd.bsky.social & other editors at @jamainternalmed.com describe challenges of using composite outcomes in clinical trials.
jamanetwork.com/journals/jam...
In this analysis, led by CP3's @bryantshuey.bsky.social, a #Medicare 7-day limit on initial #opioid prescriptions was associated with immediate large reductions in initial opioid duration and dosage. CP3 associate director Dr. Katie Suda co-authored.
Read more: journals.lww.com/annalsofsurg...
Though 27% of #Veterans surveyed reported being better able to afford 💊after co-pay restructuring, 29% reported worrying about paying for 💊, & 18% reported making tradeoffs to pay for prescriptions.
Read more: journals.sagepub.com/doi/10.1177/...
Co-authored by CP3's Dr. Katie Suda.
CP3's #MachineLearning expert @jennylociganic.bsky.social was part of a team that developed an #algorithm to effectively identify individuals at high risk of depression onset within the next 6 months & provides opportunity for early intervention.
Read more: ebooks.iospress.nl/doi/10.3233/...
The PROTECT study builds on CP3's extensive experience in creating #RiskPrediction #algorithms and deploying them in practice with paired decision support tools to help clinicians make informed decisions for safer prescribing.
www.cp3.pitt.edu/research/ris...
2/2
